Articles

June 2, 2025
Despite the potential threat of tariffs, trade policy did not factor into the India-based CRDMO’s purchase of a Baltimore biologics site from Emergent BioSolutions.
May 30, 2025
More than 300 comments have been posted in response to a Department of Commerce investigation into the importation of certain pharmaceuticals and pharma ingredients.
May 29, 2025
CEO Padraig McDonnell contends that Biovectra’s capabilities are in the “sweet spot” of GLP-1s and complex chemistries, with strong medium- and long-term growth potential.
May 28, 2025
As labs look to overcome longstanding challenges in achieving bioanalytical excellence, many are turning to digital technologies.
May 27, 2025
The Minnesota-based company is now being covered by William Blair analyst Max Smock who spoke with Pharma Manufacturing about Lifecore’s position in the CDMO landscape.
May 23, 2025
The spin-off is meant to improve operational focus and address concerns raised by its CDMO customers about potential conflicts of interest.
May 23, 2025
The threat of tariffs on pharmaceuticals and “most favored nation” drug pricing are weighing on the sector as biotech funding continues to dry up.
May 19, 2025
With a record number of FDA biosimilar approvals in 2024, CMOs specializing in biologics can expect to see higher biosimilar volumes, according to GlobalData.
May 16, 2025
PhRMA warned that President Trump’s executive order on most favored nation would jeopardize hundreds of billions of dollars in planned U.S. investments by its members.
May 14, 2025
The company warned that if the executive order goes into effect, Roche’s ability to invest $50 billion in its U.S. R&D and manufacturing sites will be in question.
May 13, 2025
CEO Bill Anderson said that the company has “considerable” production capabilities in both the U.S. and Europe but has no immediate plans to shift them.
May 9, 2025
CEO Christophe Weber said that the investment is not a new strategy and reflects the position of the U.S. as the world’s leading market for biopharma innovation.
May 8, 2025
Combined, the company projects these efforts will generate $43 billion in economic impact over the next five years.
May 6, 2025
The announcement comes after President Trump signed an executive order aimed at expediting the approval process for domestic pharmaceutical manufacturing facilities.
May 5, 2025
Expansions at sites in Le Mans and Mourenx, France have solidified the CDMO’s position in targeting the hot antibody-drug conjugate and peptide purification markets.
May 2, 2025
Dave Ricks said Lilly supports the administration’s goal of bringing pharma manufacturing back to the U.S. but doesn’t see tariffs as the “right mechanism” for reshoring.
April 30, 2025
CEO Albert Bourla said that President Trump’s threat of pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and R&D.
April 28, 2025
CEO Rob Michael told analysts that the company is investing more than $10 billion in the U.S. to support volume growth and expansion into new areas such as obesity.
April 25, 2025
The three Big Pharma companies on their earnings calls this week tried to reassure investors that they have the global footprints to mitigate the effects of tariffs.
April 24, 2025
The life sciences tools and services company said U.S.-China tariffs are expected to cut 2025 revenue by $400 million and adjusted operating income by $375 million.
April 22, 2025
Despite the widespread success of CAR T therapies, there have been challenging immunologic side effects such as cytokine release syndrome and neurotoxicity, which can now be mitigated...
April 21, 2025
The CDMO plans to build and expand small, medium, and large manufacturing facilities across Europe and the U.S. over the next three years to meet rising demand for peptides.
April 18, 2025
President Trump has threatened to impose tariffs on pharmaceuticals, as a Department of Commerce probe on drug imports gets underway. But analysts and stakeholders are skeptical...
April 16, 2025
While animal testing has been mandated for every drug since the 1930s, the drug development framework is changing — a long overdue and much needed change.
April 15, 2025
The agency has cited several drugmakers with warning letters, import alerts, and Form 483s for manufacturing lapses ranging from data integrity violations to sterility assurance...
April 14, 2025
The CDMO, with 3,200 employees at 20 locations in the U.S., Europe and India, has a global footprint to help customers navigate their R&D and manufacturing challenges.
April 11, 2025
Despite Trump pushing drugmakers to bring manufacturing back to the U.S., it remains unclear whether companies — other than Eli Lilly, J&J, and Novartis — will respond.
April 10, 2025
The company says it is investing in areas across the value chain to ensure its customers continue to enjoy the benefits of a global network with local access.
April 9, 2025
What can pharma companies do to prepare for the volatility ahead this year and beyond?